Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$942000.0.

  • Lyra Therapeutics' Change in Accured Expenses rose 6749.48% to -$942000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 million, marking a year-over-year increase of 3733.25%. This contributed to the annual value of -$6.0 million for FY2024, which is 50073.78% down from last year.
  • Lyra Therapeutics' Change in Accured Expenses amounted to -$942000.0 in Q3 2025, which was up 6749.48% from -$202000.0 recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' Change in Accured Expenses peaked at $2.3 million during Q3 2023, and registered a low of -$3.3 million during Q2 2024.
  • For the 5-year period, Lyra Therapeutics' Change in Accured Expenses averaged around $2578.9, with its median value being -$87000.0 (2022).
  • As far as peak fluctuations go, Lyra Therapeutics' Change in Accured Expenses skyrocketed by 60431.65% in 2022, and later plummeted by 256436.78% in 2023.
  • Over the past 5 years, Lyra Therapeutics' Change in Accured Expenses (Quarter) stood at $278000.0 in 2021, then skyrocketed by 604.32% to $2.0 million in 2022, then grew by 8.07% to $2.1 million in 2023, then plummeted by 127.17% to -$575000.0 in 2024, then tumbled by 63.83% to -$942000.0 in 2025.
  • Its Change in Accured Expenses was -$942000.0 in Q3 2025, compared to -$202000.0 in Q2 2025 and -$339000.0 in Q1 2025.